IPP Bureau
AbelZeta Pharma, AstraZeneca to co-develop a novel GPC3 armored CAR-T therapy in China
By IPP Bureau - December 08, 2023
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Akums acquires new facility in Baddi to enhance tablet manufacturing capacity
By IPP Bureau - December 07, 2023
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
Dr. Reddy's inks pact with Coya Therapeutics for development of sclerosis drug
By IPP Bureau - December 07, 2023
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Zydus receives final approval from the USFDA for methylene blue injection
By IPP Bureau - December 07, 2023
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
Venus Remedies gets marketing approvals from Philippines, Saudi Arabia for three drugs
By IPP Bureau - December 07, 2023
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
Lupin receives approval from U.S. FDA for Varenicline Tablets
By IPP Bureau - December 07, 2023
Varenicline Tablets, 0.5 mg and 1 mg are indicated for use as an aid to smoking cessation treatment.
Indoco Remedies receives tentative ANDA approval from USFDA for Canagliflozin Tablets
By IPP Bureau - December 07, 2023
This product will be manufactured by Indoco Remedies at their manufacturing facility located at Goa
Sun Pharmaceutical inks licensing agreement with Aclaris Therapeutics
By IPP Bureau - December 06, 2023
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Granules India received ANDA approval for Sildenafil for oral suspension
By IPP Bureau - December 06, 2023
The current annual U.S. market for Sildenafil for Oral Suspension is approximately $43 million
Mankind Pharma's PetStar ties up with Ranbir Kapoor and Neetu Kapoor for new campaign
By IPP Bureau - December 06, 2023
The esteemed duo perfectly embody the brand's core values of family, love, and the special bond we share with our pets
Zydus receives final approval from the USFDA for Ivabradine Tablets
By IPP Bureau - December 06, 2023
Ivabradine Tablets, 5 mg and 7.5 mg had annual sales of USD 136.5 mn in the United States
Briefs: Shelter Pharma and GMM Pfaudler
By IPP Bureau - December 06, 2023
GMM Pfaudler US completes acquisition of MixPro
Cupid acquires land parcel near Mumbai
By IPP Bureau - December 05, 2023
The acquisition will enable Cupid Limited to amplify its production capacity by 1.5 times the existing output
Pradeep Chakravarty joins Alembic Pharmaceuticals as Head - Global Quality
By IPP Bureau - December 05, 2023
Prior to joining Alembic, he was working with Lupin Limited for more than 11 years
AstraZeneca discontinues Phase III trials of Stabilizer-CKD and Dialize-Outcomes
By IPP Bureau - December 05, 2023
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
